Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer
Status:
Completed
Trial end date:
2017-07-07
Target enrollment:
Participant gender:
Summary
Phase I part: to determine the recommended dose, and observe the preliminary response and
safety profile of the combination of oral lapatinib with vinorelbine in patients with ErbB2
positive metastatic breast cancer.
Phase II part: to determine the progression free survival, response rate, and to evaluate the
safety profile of the combination of oral lapatinib with vinorelbine in patients with ErbB2
positive metastatic breast cancer.
Phase I part has been completed. Phase II part is underway.